Hellenic Dynamics (HELD) Competitors GBX 0.95 0.00 (0.00%) As of 02/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines HELD vs. RGT, N4P, HLN, HIK, HCM, INDV, AMYT, APH, AGY, and BXPShould you be buying Hellenic Dynamics stock or one of its competitors? The main competitors of Hellenic Dynamics include Argent BioPharma (RGT), N4 Pharma (N4P), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Allergy Therapeutics (AGY), and Beximco Pharmaceuticals (BXP). These companies are all part of the "drug manufacturers - specialty & generic" industry. Hellenic Dynamics vs. Argent BioPharma N4 Pharma Haleon Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Alliance Pharma Allergy Therapeutics Beximco Pharmaceuticals Argent BioPharma (LON:RGT) and Hellenic Dynamics (LON:HELD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Do insiders & institutionals believe in RGT or HELD? 1.1% of Argent BioPharma shares are owned by institutional investors. Comparatively, 0.1% of Hellenic Dynamics shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by company insiders. Comparatively, 72.9% of Hellenic Dynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer RGT or HELD? In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled Hellenic Dynamics'average media sentiment score. Company Overall Sentiment Argent BioPharma Neutral Hellenic Dynamics Neutral Does the MarketBeat Community favor RGT or HELD? Argent BioPharma and Hellenic Dynamics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformArgent BioPharmaN/AN/AHellenic DynamicsN/AN/A Which has preferable earnings & valuation, RGT or HELD? Hellenic Dynamics is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24N/AHellenic DynamicsN/AN/A-£5.22M-£3.55-0.27 Is RGT or HELD more profitable? Hellenic Dynamics has a net margin of 0.00% compared to Argent BioPharma's net margin of -1,960.39%. Argent BioPharma's return on equity of 420.08% beat Hellenic Dynamics' return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharma-1,960.39% 420.08% -108.57% Hellenic Dynamics N/A -364.21%N/A SummaryHellenic Dynamics beats Argent BioPharma on 5 of the 8 factors compared between the two stocks. Get Hellenic Dynamics News Delivered to You Automatically Sign up to receive the latest news and ratings for HELD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HELD vs. The Competition Export to ExcelMetricHellenic DynamicsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£1.40M£2.35B£5.84B£2.64BDividend YieldN/A2.92%4.75%4.98%P/E Ratio-0.274.2726.70162.45Price / SalesN/A733.09435.29314,061.87Price / CashN/A10.2538.0128.13Price / Book0.627.507.645.16Net Income-£5.22M£20.70B£3.19B£5.76B7 Day PerformanceN/A-0.11%-2.12%-1.01%1 Month PerformanceN/A0.00%-0.45%-0.85%1 Year Performance-71.21%97.98%16.26%39.61% Hellenic Dynamics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A-0.27N/ARGTArgent BioPharmaN/AN/AN/AN/A£3.10MN/A-24.12N/AGap DownHigh Trading VolumeN4PN4 PharmaN/AGBX 0.60+4.3%N/A-23.2%£2.37M£23,524.00-55.005Gap DownHigh Trading VolumeHLNHaleon0.4924 of 5 starsGBX 390.50+0.0%GBX 415+6.3%+20.4%£35.30B£11.26B3,254.1725,408HIKHikma Pharmaceuticals1.789 of 5 starsGBX 2,338flatGBX 2,436.67+4.2%+15.6%£5.19B£3.02B3,596.929,100News CoverageHCMHUTCHMEDN/AGBX 211-3.2%N/A+11.8%£1.80B£610.81M-5,275.001,760Positive NewsGap UpINDVIndivior2.4978 of 5 starsGBX 814.50+6.5%GBX 1,650+102.6%-49.2%£1.05B£1.15B-1,018.131,000News CoverageAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.8367 of 5 starsGBX 61.50flatGBX 6,250+10,062.6%+43.6%£332.45M£183.15M-1,025.0091,000AGYAllergy TherapeuticsN/AGBX 6.40-2.1%N/A+161.5%£305.28M£53.26M-106.67612BXPBeximco PharmaceuticalsN/AGBX 39.67+3.0%N/A-7.3%£176.97M£43.08B495.885,500Gap Up Related Companies and Tools Related Companies Argent BioPharma Competitors N4 Pharma Competitors Haleon Competitors Hikma Pharmaceuticals Competitors HUTCHMED Competitors Indivior Competitors Amryt Pharma Competitors Alliance Pharma Competitors Allergy Therapeutics Competitors Beximco Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HELD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hellenic Dynamics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hellenic Dynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
